Latest News

ANNOUNCEMENT – Aspen Pharmacare – URGENT MEDICINE RECALL FOR PRODUCT CORRECTION of SPAN K (potassium chloride) 600mg Tablets TGA reference: RC-2017-RN-00300-1

April 21, 2017

The bottle cap on Span K (potassium chloride) 600mg tablets is not child resistant. Apsen Pharmacare is conducting a recall for product correction to replace the current plain white cap with an enclosed child resistant cap. Future stock will include a child resistant cap.


ANNOUNCEMENT – Aspen AstraZeneca Anaesthetics Portfolio Agreement

June 10, 2016

Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca AB and AstraZeneca UK (“AstraZeneca”) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca’s global (excluding the USA) anaesthetics portfolio (“the Transaction”).


ANNOUNCEMENT: Divestment of portfolio to Strides

September 1, 2015

As of 1 September 2015 Aspen has divested to Strides (Australia) Pharma Pty Ltd a portfolio of its products commercialised in Australia and New Zealand. The range primarily includes the Aspen Generics Product Portfolio and business, including the Chemists’ Own range. Strides, to be called Arrow Pharmaceuticals in Australia, has a core focus on generic product development, and with its strong manufacturing and procurement capabilities has better opportunities to promote and grow this portfolio.


WINNER Aspen Values Award – JOHN SEGEDIN, Warehouse Leading Hand, Operations, Dandenong

November 11, 2014

It is with great pleasure and pride we communicate that at the 2014 Aspen Global Recognition Awards held in Johannesburg South Africa on Friday 7 November, John Sedgedin was announced the winner of the Aspen Values Award.



S26 Original Progress Withdrawal – Update

July 16, 2014

Aspen Nutritionals takes product safety very seriously and we are in the process of investigating the issue. We have not received any further complaints of this nature.


Voluntary Withdrawal of S-26 Original Progress Formula, Batch Number 40727482A2

July 15, 2014

Aspen Nutritionals Australia Pty Ltd is very concerned that a customer has reported finding a lizard in a tin of S-26 Original Progress formula, and is voluntarily withdrawing the affected batch number 40727482A2 while it investigates the issue.  No other products or batches are affected, and consumers can continue to use these with confidence.


Ferinject® (ferric carboxymaltose) 10ml (500mg) available on the Pharmaceutical Benefits Scheme (PBS) from the 1st June, 2014

June 1, 2014

Aspen Australia is pleased to advise that from the 1st June, 2014 Ferinject® (ferric carboxymaltose) 10ml (500mg) is available on the Pharmaceutical Benefits Scheme (PBS) as a drug for iron deficiency anaemia.# Ferinject® (ferric carboxymaltose) is available in Australia for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests.


Honorary Doctor of Commerce Degree conferred on Stephen Saad

April 16, 2014

Port Elizabeth – The Nelson Mandela Metropolitan University (NMMU) today conferred the degree of Doctor of Commerce (honoris causa) on Stephen Saad, Aspen Group Co-Founder and Chief Executive. Chancellor of the NMMU, Santie Botha said, ‘’It is an honour for NMMU to confer this honorary degree on Stephen Saad. His vision and drive in the world of business is inspiring and as NMMU we acknowledge the turn-around he orchestrated in a Port Elizabeth-based company that provides jobs to people in an economically struggling province’’.


Perrigo Company plc Announces Acquisition Of OTC Products In Australia

March 4, 2014

DUBLIN, Feb. 28, 2014 /PRNewswire/ — Perrigo Company plc (NYSE: PRGO;TASE) announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc. for $51 million in cash. The products are primarily sold through the mass retail channel and include the Herron® range of analgesics, vitamins and supplements. This basket of products is expected to generate at least $20 million in annual revenue.


New Supply Conditions Relating to Di-Gesic and Doloxene

January 8, 2014

On 1 January 2014 new conditions relating to the prescribing and dispensing of Di-Gesic (dextropropoxyphene HCl 32.5mg/paracetamol 325mg) and Doloxene (dextropropoxyphene napsylate) came into effect.